FibroGen Appoints New Chief Medical Officer
Ticker: KYNB · Form: 8-K · Filed: Sep 6, 2024 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, biotech
TL;DR
FibroGen brings in Gilead exec Nielsen as new CMO to drive clinical programs.
AI Summary
FibroGen, Inc. announced on August 30, 2024, the appointment of Dr. K. Peter R. Nielsen as Chief Medical Officer and Executive Vice President. Dr. Nielsen previously served as Senior Vice President, Clinical Development at Gilead Sciences, Inc. This appointment is part of the company's ongoing efforts to advance its clinical programs.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the direction and execution of FibroGen's drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in R&D leadership, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- Dr. K. Peter R. Nielsen (person) — Appointed Chief Medical Officer
- Gilead Sciences, Inc. (company) — Dr. Nielsen's former employer
- August 30, 2024 (date) — Date of earliest event reported
FAQ
What is the effective date of Dr. Nielsen's appointment?
The filing reports the earliest event as August 30, 2024, indicating this is the effective date or the date the event was reported.
What was Dr. Nielsen's previous role before joining FibroGen?
Dr. Nielsen previously served as Senior Vice President, Clinical Development at Gilead Sciences, Inc.
What is Dr. Nielsen's new title at FibroGen?
Dr. Nielsen has been appointed as Chief Medical Officer and Executive Vice President.
What is FibroGen's primary business sector?
FibroGen, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.
Where is FibroGen, Inc. headquartered?
FibroGen, Inc. is headquartered at 409 Illinois Street, San Francisco, California, 94158.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-09-06 16:11:01
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
Filing Documents
- fgen-20240830.htm (8-K) — 35KB
- 0000950170-24-104395.txt ( ) — 145KB
- fgen-20240830.xsd (EX-101.SCH) — 24KB
- fgen-20240830_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: September 6, 2024 By: /s/ Michael Lowenstein Michael Lowenstein Chief Legal Officer